Goodsaid Remarks at Molecular Medicine Tri-Conference To have your event featured here, contact Editor's note: These remarks have been very lightly edited.Frederico Goodsaid is associate director for operations in genomics, Office of Clinical Pharmacology, Office of Translational Science,...
Web Extra: Frederico Goodsaid Remarks To have your event featured here, contact Editor's note: These remarks have been very lightly edited.Frederico Goodsaid is associate director for operations in genomics, Office of Clinical Pharmacology, Office of Translational Science,...
Russell Transcript: FDA Warms to Pathway Tool Use To have your event featured here, contact By John Russell May 12, 2008 | Speaking at Cambridge Healthtech Institute's annual Molecular Medicine Tri-Conference*, Frederico Goodsaid of FDA delivered one of the clearest explanations yet of...
FDA Panel Nixes 'Abuse-Proof' OxyContin from WebMD a health information Web site for patients May 11, 2008 A panel of expert advisors to the FDA took a dim view Monday of efforts by OxyContin's manufacturer to market a new form of the prescription painkiller designed to cut...
King Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript Brian A.Markison - Chairman, President and CEO Joseph Squicciarino - CFO Eric G.
Carter - Chief Science Officer Analysts Donald Ellis - Thomas Weisel Partners Gregory Gilbert - Merrill Lynch Ian Sanderson - Cowen And Company Robert...
Adolor Provides Regulatory Update on Entereg(R) (alvimopan) EXTON, Pa.--(HSMN NewsFeed)--Adolor Corporation (Nasdaq:ADLR ) announced today that the U.S.Food and Drug Administration (FDA) has communicated to the company that it will not be issuing an action letter on the NDA for Entereg...
Albemarle Optimizes Smallpox Drug Candidate for SIGA BATON ROUGE, La.Albemarle Corporation (NYSE: ALB), a leading global provider of custom pharmaceutical manufacturing services, was selected by SIGA Technologies (Nasdaq: SIGA), a company specializing in the development of pharmaceutical...
BioSante Pharmaceuticals Reports First Quarter 2008 Financial Results LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc.(NASDAQ:BPAX - News) today reported its March 31, 2008 financial results and cash balance for the first quarter ended March 31, 2008.
BioSante incurred a net loss...
BioSante Pharmaceuticals Reports First Quarter 2008 Financial Results LINCOLNSHIRE, Ill.-- (BUSINESS WIRE) -- BioSante Pharmaceuticals, Inc.(NASDAQ:BPAX) today reported its March 31, 2008 financial results and cash balance for the first quarter ended March 31, 2008.
BioSante incurred a net loss of...
::: Eurand Reports First Quarter 2008 Key Achievements and Financial Results * EUR-1008 (Zentase(r)) NDA accepted and granted priority review status by FDA * EUR-1008 (Zentase(r)) MAA received eligibility for centralized review procedure in European Union * In-licensed corticosteroid product for inflammatory...
New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Comp TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Many strong acting pain medications have bothersome side effects.These can include nausea and vomiting with short-term use, and constipation with longer, chronic use.
Such symptoms can lead...
New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Comp TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Many strong acting pain medications have bothersome side effects.These can include nausea and vomiting with short-term use, and constipation with longer, chronic use.
Such symptoms can lead...
Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerabi TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Osteoarthritis is a painful and potentially debilitating condition that affects almost 50 million people in the United States.It is caused by deterioration of cartilage in bone joints.
The...
New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Su Novel Pain Medicine Studied in Patients Following Bunionectomy TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Many foot-surgery patients experience intense pain for several days following removal of a bunion, one of the most common foot...
Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerabi TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Osteoarthritis is a painful and potentially debilitating condition that affects almost 50 million people in the United States.It is caused by deterioration of cartilage in bone joints.
The...
Colorado BioScience Association Announces Nine New Board Members (SkyNewswire.com)--DENVER--Nine new board members have been elected to the Colorado BioScience Association (CBSA) 40-member Board of Directors.The announcement is made by Chris Shapard, CBSA Deputy Director, who says the election...
FDA Advisory Committee Votes in Favor of Approval of Fospropofol Disodium Injection for Sedation /PRNewswire/ -- Eisai Corporation of North America and its U.S.subsidiary, MGI PHARMA, INC., today announced that the U.S.
Food and Drug Administration (FDA) Advisory Committee on Anesthetic and Life Support Drugs (ALSDAC)...
BioSante Pharmaceuticals Reports First Quarter 2008 Financial Results , 5:00 PM EST News source: Business Wire BioSante Pharmaceuticals, Inc.(NASDAQ:BPAX) today reported its March 31, 2008 financial results and cash balance for the first quarter ended March 31, 2008.
BioSante incurred a net loss of...
BioSante Pharmaceuticals Reports First Quarter 2008 Financial Results BioSante Pharmaceuticals, Inc.(NASDAQ:BPAX) today reported its March 31, 2008 financial results and cash balance for the first quarter ended March 31, 2008.
BioSante incurred a net loss of approximately $3.6 million or ($0.13) per share...
Microbix to spin off urokinase assets into a new company Microbix Biosystems Inc.has announced that it intends to spin off its Urokinase assets into a new private company, Klarogen Biotherapeutics Inc., which would become the sole commercial-scale manufacturer and supplier of the clot...
Repros Therapeutics Inc. Reports First Quarter 2008 Financial Results and Provides Clinical Development Progra Repros Therapeutics (NasdaqGM:RPRX) today announces financial results for the first quarter ended March 31, 2008 and provides a clinical development program overview.Financial Results Total revenues which consisted of only interest income...
Microbix to spin off Urokinase into newly formed Klarogen Biotherapeutics Klarogen to acquire all remaining Urokinase inventory, sales and marketing infrastructure and NDA from ImaRx upon completion of financing09 May 2008 - Microbix Biosystems Inc.announced that it intends to spin off its Urokinase...
Spectrum sells off generic drugs Specturm Pharmaceuticals has sold its abbreviated NDAs for its injectable generic drugs, ondansetron, carboplatin, fludarabine, and mitoxantrone, to Sagent Pharmaceuticals.Sagent, which made our list of the , brings finished...
Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference Presentation Will be Webcast Live and Archived on Company's Website ROCKVILLE, Md., May 08, 2008 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of...
BEMA Fentanyl Phase III Data Demonstrating Efficacy And Tolerability To Be Presented At American Pain Society BioDelivery Sciences International, Inc.and commercial partner Meda Pharmaceuticals will present today and tomorrow, data from Phase III clinical pivotal trials for BEMA Fentanyl, a potential treatment for breakthrough pain (BTP) in...
